August 2025—EntroGen announced that its CRCdx RAS mutation detection kit has received national coverage from the Centers for Medicare and Medicaid Services. CRCdx is an FDA-approved, real-time PCR-based companion diagnostic for use in identifying patients eligible for treatment with Vectibix (panitumumab), based on the absence of KRAS and NRAS mutations.
EntroGen, 818-716-1070